Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp fall in adjusted earnings for the fourth quarter of 2023, despite
MRK Earnings: Highlights of Merck’s Q4 2023 financial results
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp fall in adjusted earnings for the fourth quarter of 2023, despite a modest increase in revenues. Fourth-quarter worldwide sales increased 6% year-over-year to $14.6 billion, mainly reflecting the sustained